🇺🇸 FDA
Patent

US 7598225

Generation of immune response to prostate-specific antigen (PSA)

granted A61KA61K2039/5256A61K2039/55522

Quick answer

US patent 7598225 (Generation of immune response to prostate-specific antigen (PSA)) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 06 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/5256, A61K2039/55522, A61K2039/55555, A61K39/00